Skip to main content

Table 1 Different doses of carcinogen (DEN/CCl4 /DEN+CCl4) and harmalol during 0–21 weeks of treatment in male Swiss albino mice (Mus musculus)

From: Pharmaceutical efficacy of harmalol in inhibiting hepatocellular carcinoma

  1. Here “H”, “D”, and “C” denote harmalol (10 mg/kg B.W. per week) for 9 weeks, DEN (24 mg/kg B.W. per week) for 12 weeks, and CCl4 (0.2 ml/kg B.W. per week) for 4 weeks, respectively; “-” means continuously receive vehicle of normal saline (0.2 ml/kg, B.W. I.P. per week); and “S” stands for sacrifice